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infarction (TIMI) flow grade 0, post-PCI TIMI flow 
< grade 3, and ST-elevation resolution <70%.
Conclusions: In patients undergoing PCI for STEMI, VT/VF
markedly increases the risk of mortality at 90 days, particu-
larly when the VT/VF occurs after PCI.
Perspective: VT/VF in the first 48 hours of STEMI previ-
ously was thought to not have long-term prognostic
implications. The results of this study and others indicate
that VT/VF is a strong independent predictor of death at 90
days. Whether early treatment with an implantable car-
dioverter defibrillator improves outcomes in these patients is
unclear and requires further study.  
Summary written by: Fred Morady, MD
General Cardiology
Cardiorespiratory Fitness as a Quantitative
Predictor of All-Cause Mortality and Cardiovascular
Events in Healthy Men and Women: A Meta-Analysis
Kodama S, Saito K, Tanaka S, et al.
JAMA 2009;301:2024–2035.
Study Design: What is the long-term outcome after prophy-
lactic coronary revascularization prior to major vascular
surgery in high-risk patients?
Methods: This meta-analysis included 33 studies identified after
a systemic literature review of observational cohort studies
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Arrhythmias
Incidence of and Outcomes Associated With
Ventricular Tachycardia or Fibrillation in Patients
Undergoing Primary Percutaneous Coronary
Intervention
Mehta RH, Starr AZ, Lopes RD, et al., on behalf of the APEX AMI
Investigators.
JAMA 2009;301:1779–1789.
Study Design: Does ventricular tachycardia/ventricular fibrilla-
tion (VT/VF) affect prognosis in patients undergoing
percutaneous coronary intervention (PCI) in the setting of
ST-elevation myocardial infarction (STEMI)?
Methods: This was a retrospective analysis of a clinical trial in
which 5,745 patients (mean age 61 years) presenting with
STEMI underwent PCI. Sustained VT/VF was classified as
early (i.e., before or during PCI) or late (i.e., after PCI).
The 1° outcome was 90-day mortality.
Results: VT/VF occurred in 5.7% of patients. The timing of
VT/VF was early in 205 patients and late in 117 patients.
The VT/VF occurred within 48 hours of STEMI onset in
90% of patients. The 90-day mortality was 3.6% in patients
without VT/VF, 17.2% in patients with early VT/VF, and
33.3% in patients with late VT/VF. Early and late VT/VF
were associated with a 2.3- and 5.6-fold higher risk of death
at 90 days, respectively. Sudden cardiac death accounted for
40% of deaths. The strongest predictors of VT/VF were
advanced Killip class, pre-PCI thrombolysis in myocardial
of MIs, 2,318 cases of CHD, 1,127 strokes, and 2,892 cases
for all-cause mortality during 163,000 person-years of fol-
low-up (study follow-up ranged from 3.5 to 10.1 years). The
mean hemoglobin A1c concentration (HbA1c) was 0.9%
lower for participants given intensive versus standard treat-
ment. Increased intensity glycemic control resulted in a 17%
reduction in events of nonfatal MI (odds ratio, 0.83; 95%
confidence interval, 0.75-0.93), and a 15% reduction in
CHD events (0.85, 0.77-0.93), but had no significant effect
on incident stroke, heart failure, or all-cause mortality.
Hypoglycemia occurred in 38.1% of intensive treatment
compared to 28.6% of standard treatment.
Conclusions: Lowered HbA1c concentration from intensive
glycemic control significantly reduces coronary events with-
out an increased risk of death.
Perspective: The benefit of tighter glycemic control appears
worth the risk, but the impact of increased hypoglycemia is
not clear from this analysis. The authors point out that the
mean (weighted) mortality rate of participants on standard
treatment is 18.6 per 1,000 person-years of follow-up, and
those who achieve a 0.9% reduction from a mean HbA1c
concentration of 7.8% at baseline have about two less MIs
and three fewer CHD events for every 200 individuals
treated for 5 years. This benefit is modest compared to the
benefit of lipid and blood pressure therapies in diabetes and
supports aggressive treatment of all cardiovascular risk fac-
tors, including stricter glycemic control, which is also
associated with a decrease in microvascular complications. 
Summary written by: Melvyn Rubenfire, MD 
Health Care-Associated Native Valve Endocarditis:
Importance of Non-Nosocomial Acquisition
Benito N, Miró JM, de Lazzari E, et al., on behalf of the ICE-PCS
(International Collaboration on Endocarditis Prospective Cohort Study)
Investigators.
Ann Intern Med 2009;150:586–594. 
Study Question: What are the characteristics and outcomes of
community-associated, and nosocomial and non-nosocomial
health care-associated native valve infective endocarditis (IE)?
Methods: A prospective study was conducted from June 2000
to August 2005 at 61 hospitals in 28 countries, in patients
with definite native valve IE and no history of intravenous
drug use. Clinical and echocardiographic findings, microbiol-
ogy, complications, and mortality were recorded. IE was
classified as community-acquired if it was diagnosed within
48 hours of admission in a patient without extensive out-of-
hospital contact with health care. IE was considered
nosocomial health care-associated if it occurred in a patient
hospitalized for more than 48 hours before the onset of signs
or symptoms, and non-nosocomial health care-associated if it
published between 1966 and 2008. Eligibility criteria included
the assessment of CRF by exercise stress testing with reported
maximal aerobic capacity in metabolic equivalent (MET)
units. Outcomes of interest included all-cause mortality, and
coronary heart disease (CHD) or cardiovascular disease
(CVD). Only studies with patients having a disease that was a
major risk factor such as diabetes or hypertension, CHD, or
chronic heart failure were included.
Results: A total of 102,980 participants were included for the
analysis of all-cause mortality and 84,323 for the analysis of
CHD/CVD mortality. Pooled relative risk of all-cause mor-
tality and CHD/CVD events per 1 MET higher level of
maximal aerobic capacity were 0.87 (95% confidence interval
[CI], 0.84-0.90) and 0.85 (95% CI, 0.82-0.88), respectively.
Subjects with low CRF were at increased risk for all-cause
mortality compared to subjects with high CRF (relative risk
[RR], 1.70; 95% CI, 1.51-1.92) and CHD/CVD events (RR,
1.56; 95% CI, 1.39-1.75). Subjects with low CRF were also
at increased risk for events compared to subjects with inter-
mediate CRF (RR, 1.40; 95% CI, 1.32-1.48 for all-cause
mortality and RR, 1.47; 95% CI, 1.35-1.61 for CHD/CVD).
Subjects with a maximal aerobic capacity of 7.9 METs or
more had significantly lower rates of all-cause mortality and
CHD/CVD events.
Conclusions: Better CRF was associated with a lower risk for
all-cause mortality and CHD and/or CVD events.
Perspective: These findings support the need for advising
patients to be physically active as a key component of pre-
vention recommendations. 
Summary written by: Elizabeth A. Jackson, MD 
Effect of Intensive Control of Glucose on
Cardiovascular Outcomes and Death in Patients
With Diabetes Mellitus: A Meta-Analysis of
Randomised Controlled Trials
Ray KK, Seshasai SR, Wijesuriya W, et al.
Lancet 2009;373:1765–1772.
Study Design: Does intensive control of glucose reduce
macrovascular events and all-cause mortality in individuals
with type 2 diabetes mellitus?
Methods: A meta-analysis was conducted of five prospective
randomized controlled trials of 33,040 participants to assess
the effect of an intensive glucose-lowering regimen on death
and cardiovascular outcomes compared with a standard regi-
men. Endpoints included information about events of nonfatal
myocardial infarction (MI), coronary heart disease (CHD)
(fatal and nonfatal MI), stroke, and all-cause mortality.
Results: The five trials provided information on 1,497 cases
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Results: There was no significant change in the pharmacoki-
netics (active metabolite levels) or the platelet inhibition in
response to prasugrel with presence (or absence) of at least
one reduced-function allele for any of the CYP genes tested
(CYP2C19, CYP2C9, CYP2B6, CYP3A5, and CYP1A2).
Among patients with acute coronary syndromes who were
randomized to prasugrel, there was no association between the
genotype and the risk of cardiovascular death, myocardial
infarction, or stroke. A significant interaction was noticed
between the impact of the genotype and the randomization
arm with respect to ischemic events.
Conclusions: Polymorphism of CYP does not influence the
active drug metabolite levels, inhibition of platelet aggrega-
tion, or the risk of cardiovascular events in patients treated
with prasugrel.
Perspective: Among patients treated with clopidogrel, presence
of reduced-function CYP2C19 alleles is associated with an
exaggerated hazard of major adverse cardiovascular events. It
seems that the clinical effect of prasugrel is relatively inde-
pendent of the genotype, and this may partially explain the
superiority of prasugrel observed in the TRITON-TIMI 38
trial. These data, in combination with the authors’ earlier
work (Mega JL, et al., N Engl J Med 2009;360:354–62), pro-
vide a strong rationale for pharmacogenetically guided
antiplatelet therapy.  
Summary written by: Hitinder S. Gurm, MD 
Adverse Cardiovascular Outcomes in Women With
Nonobstructive Coronary Artery Disease: A Report
From the Women's Ischemia Syndrome Evaluation
Study and the St James Women Take Heart Project
Gulati M, Cooper-DeHoff RM, McClure C, et al.
Arch Intern Med 2009;169:843-850.
Study Question: Are women with nonobstructive coronary
artery disease (CAD) at increased risk for cardiovascular
(CV) events?
Methods: Women with suspected ischemia and evidence of
obstructive CAD on angiography from the Women’s
Ischemia Syndrome Evaluation (WISE) study were com-
pared to women from the St James Women Take Heart
(WTH) project, a community-based sample of women with
no history of heart disease at baseline, followed for 10 years.
Nonobstructive disease was defined as all coronary arteries
with less than a 50% stenosis. Two groups of WISE subjects
were created: one with no evidence of CAD and the other
with nonobstructive CAD. Subjects from WISE were
matched on age and race with subjects from WTH. Mean
follow-up time was 5.2 years. Outcomes of interest included
CV events (myocardial infarction, stroke, heart failure
requiring hospitalization), and death.
was diagnosed within 48 hours of admission in a patient with
extensive out-of-hospital contact with health care.
Results: Health care-associated native valve endocarditis was
present in 557 (34%) of 1,622 patients, including 303 (54%)
with nosocomial infection and 254 (46%) with non-nosoco-
mial infection. Staphylococcus aureus was the most common
cause of health care-associated infection (nosocomial, 47%;
non-nosocomial, 42%; p = 0.30); a high proportion of
patients had methicillin-resistant S. aureus (nosocomial, 57%;
non-nosocomial, 41%; p = 0.014). Fewer patients with
health care-associated IE had cardiac surgery (41% vs. 51%
of community-associated cases; p < 0.001), but more of the
former patients died (25% vs. 13%; p < 0.001). Multivariable
analysis confirmed greater mortality associated with health
care-associated IE (incidence risk ratio, 1.28 [95% confi-
dence interval, 1.02-1.59]).
Conclusions: More than one-third of cases of native valve IE
involve contact with health care, and out-of-hospital acquisi-
tion of infection is common. Clinicians should recognize
that outpatients with extensive out-of-hospital health care
contacts who develop endocarditis have clinical characteris-
tics and outcomes similar to those of patients with
nosocomial infection.
Perspective: It makes sense that patients with frequent expo-
sure to health care interventions and other aspects of the
health care system are at risk of infection with organisms
similar to hospitalized patients. This study helps define this
third group of patients. Perhaps this would be easier with a
simple change of labels. Linguistically, there is no reason
that the term ‘nosocomial’ should apply exclusively to dis-
eases acquired within the walls of a hospital; simple contact
with health care should be enough.  
Summary written by: David S. Bach, MD  
Cytochrome P450 Genetic Polymorphisms and the
Response to Prasugrel. Relationship to Pharma-
cokinetic, Pharmacodynamic, and Clinical Outcomes 
Mega JL, Close SL, Wiviott SD, et al.
Circulation 2009;119:2553–60. 
Study Question: How does polymorphism of cytochrome P450
(CYP) impact the pharmacodynamics and pharmacokinetics
of, and clinical response to prasugrel? 
Methods: The authors studied the associations between poly-
morphisms of CYP genes, plasma concentrations of active
drug metabolite, and platelet inhibition in response to 
prasugrel in 238 healthy subjects. They further studied the
association between these genetic variants with outcomes in
a cohort of 1,466 patients randomized to treatment with
prasugrel in the TRITON-TIMI 38 trial.
JACC Vol. 54, No. 2, 2009
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Results: A total of 540 women from the WISE study (58.9%
with normal coronary arteries and 41.1% with nonobstructive
CAD) were compared to 1,000 women from the WTH study.
Rates of obesity, family history of CAD, hypertension, and
diabetes were lower among the WTH compared to the WISE
women. After adjustment for CV risk factors, the 5-year
annualized CV event rates were highest for women with
nonobstructive (event rate 16%), followed by women with
normal coronary arteries (event rate 7.9%). Women in WTH
had the lowest event rate at 2.4%. The CV event rate was
highest among women with four or more CV disease (CVD)
risk factors: 25.3% for women with nonobstructive CAD,
13.9% for women with normal coronary arteries, and 6.5% for
asymptomatic women. Increasing age was significantly related
to event rates among women with nonobstructive CAD.
Conclusions: Women with symptoms and signs suggestive of
ischemia, but without obstructive CAD, are at risk for
future CVD events, particularly those with multiple CVD
risk factors.
Perspective: These findings support the need for risk factor
prevention, even when coronary arteries appear nonobstructed
or normal by angiography. Whether risk factor modification
will prevent events in these women remains unanswered.
Summary written by: Elizabeth A. Jackson, MD 
Myocarditis
Cooper LT Jr.
N Engl J Med 2009;360:1526–1538.
Perspective: The following are 10 points to remember about
myocarditis:  
1. Epidemiology: The true incidence of myocarditis is
unknown. The greatest burden of pediatric myocarditis may
not be apparent for 6-12 years after diagnosis, when children
die or require orthotopic heart transplantation for chronic
dilated cardiomyopathy. 
2. Etiology: Viral and postviral myocarditis remain major
causes of acute and chronic dilated cardiomyopathy.
Seroepidemiologic data are difficult to discern because of
the heterotopic effect of enteroviruses, which may result in
an amnestic antibody response to other coxsackievirus B
strains. The spectrum of viruses in endomyocardial biopsy
samples has shifted from coxsackievirus B to adenovirus in
the late 1990s and, in the past 5 years, to parvovirus B19
and other viruses, in the United States and Germany. 
3. Etiology: In Central and South America, Trypanosoma
cruzi infection can present as acute myocarditis, sometimes
with right bundle branch block or left anterior fascicular
block. Myocarditis is the most common cardiac pathological
finding at autopsy of HIV patients (~50% of cases). 
4. Etiology: Anticonvulsants, antibiotics, and antipsychotics,
have been associated with hypersensitivity myocarditis.
Eosinophilic myocarditis has been associated with the Churg–
Strauss syndrome, Loffler’s endomyocardial fibrosis, cancer,
and parasitic, helminthic, or protozoal infections and with vac-
cination for several diseases, including smallpox. 
5. Etiology: Giant-cell myocarditis should be considered in
acute dilated cardiomyopathy associated with thymoma,
autoimmune disorders, ventricular tachycardia, or high-grade
heart block. 
6. Pathophysiology: In animal models, the progression from
acute injury to chronic dilated cardiomyopathy is a three-
stage process: 1) Acute injury leads to cardiac damage, 2)
exposure of intracellular antigens such as cardiac myosin, and
3) activation of the innate immune system that results in
mistaken recognition of endogenous heart antigens as patho-
genic entities. 
7. Clinical picture: Although a viral prodrome is classically
associated with myocarditis, reported symptoms are highly
variable. Children often have a more fulminant presentation. 
8. Tests: Troponin I has high specificity (89%), but limited
sensitivity (34%) in the diagnosis of myocarditis. The sensi-
tivity of the electrocardiogram for myocarditis is low (47%).
Fulminant myocarditis may be distinguished from echocar-
diography by acute myocarditis by a smaller left ventricular
cavity size and increased wall thickness. Endomyocardial
biopsy should be done in unexplained, new-onset heart fail-
ure of less than 2 weeks’ duration in association with a
normal size or dilated left ventricle and hemodynamic com-
promise, for suspected fulminant myocarditis.
9. Diagnostic procedures: The Dallas diagnostic pathologic
criteria are limited by variability in interpretation, lack of prog-
nostic value, and low sensitivity, whereas criteria based on
immunoperoxidase staining have greater sensitivity and may
have prognostic value. Preliminary data suggest that noninva-
sive cardiac MRI is an alternative method for diagnosis without
the risks of biopsy. Clinicopathological criteria may distinguish
fulminant lymphocytic myocarditis from acute lymphocytic
myocarditis and introduce prognostically useful data that are
better than pathologic criteria.
10. Treatment: The mainstay of treatment for acute myocardi-
tis is supportive therapy for left ventricular dysfunction. Most
patients will improve with a standard heart failure regimen.
Because most are diagnosed weeks after viral infection, it is
unlikely that antiviral therapy would be provided early enough
to be of benefit. Interferon beta may be effective in patients
with viral persistence in chronic, stable dilated cardiomyopa-
thy. The routine use of intravenous immunoglobulin for acute
myocarditis in adults is not recommended. Immuno-
suppression is not beneficial in the routine therapy of acute
lymphocytic myocarditis. Unlike lymphocytic myocarditis,
transplant-free survival in patients with giant-cell myocarditis
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Interventional Cardiology
Long-Term Safety and Efficacy of Drug-Eluting
Versus Bare-Metal Stents in Sweden
James SK, Stenestrand U, Lindback J, et al., on behalf of the SCAAR
Study Group.
N Engl J Med 2009;360:1933–1945.
Study Question: What is the long-term safety and efficacy of
drug-eluting stents (DES)?
Methods: The authors evaluated 47,967 patients in Sweden
who received a coronary stent and were entered into the
Swedish Coronary Angiography and Angioplasty Registry
between 2003 and 2006 and for whom complete follow-up
data were available for 1-5 years (mean 2.7). In the primary
analysis, the investigators compared patients who received
one DES (10,294 patients) with those who received one
bare-metal stent (BMS) (18,659).
Results: Analysis of outcome was based on 2,380 deaths and
3,198 myocardial infarctions (MIs). There was no overall
difference between the group that received DES versus BMS
in the combined endpoint of death or MI or the individual
endpoints of death and MI, and no significant difference in
outcome among subgroups stratified according to the indica-
tion for stent implantation. Patients who received DES in
2003 had a significantly higher rate of late events than
patients who received BMS in the same year, but there was
no difference in outcome among patients treated in later
years. The average rate of restenosis during the first year was
3.0 events per 100 patient-years with DES versus 4.7 with
BMS; 39 patients would need to be treated with DES to
prevent one case of restenosis. Among high-risk patients, the
adjusted risk of restenosis was 74% lower with DES com-
pared to BMS, and only 10 lesions would need to be treated
to prevent one case of restenosis. 
Conclusions: Compared with BMS, DES are associated with a
similar long-term incidence of death or MI, and provide a
significant decrease in the rate of restenosis.
Perspective: The present study did not demonstrate a difference
in long-term survival or in the risk of MI between patients
who received DES versus BMS. Among patients who required
stents less than 3 mm in diameter and more than 20 mm in
length, there was a 70% relative reduction and 10% absolute
reduction in clinical restenosis. The data suggest that use of
DES is safe, and in patients with lesions at high risk for
restenosis, is very effective in reducing the risk of clinical
restenosis. DES appears to be the preferred stent in patients at
high risk of restenosis provided that the patient is able to
afford and tolerate long-term dual antiplatelet therapy.  
Summary written by: Debabrata Mukherjee, MD  
may be prolonged with a combination of cyclosporine and
steroids. Patients recovering from acute myocarditis should
refrain from aerobic activity for a period of months after the
clinical onset of the disease.
Summary written by: Ragavendra R. Baliga, MBBS 
Heart Failure/Transplant
Influence of Patient Age and Sex on Delivery of
Guideline-Recommended Heart Failure Care in the
Outpatient Cardiology Practice Setting: Findings
From IMPROVE HF
Yancy CW, Fonarow GC, Albert NM, et al.
Am Heart J 2009;157:754–762.
Study Question: What is the influence of age and gender on
delivery of optimal heart failure (HF) therapy?
Methods: The study cohort was comprised of 15,381 outpa-
tients with chronic HF and left ventricular ejection fraction
≤35% from the IMPROVE HF registry; 71.1% (n = 8,770)
were male. Median age of male patients was 70, and 72 for
females. The investigators stratified data and then analyzed
the patients as male/female and by age tertiles with general-
ized estimating equation models constructed for seven care
measures.
Results: There was no difference between the use of
angiotensin-converting enzyme inhibitors, angiotensin-recep-
tor blockers, beta-blockers, aldosterone inhibitors, and cardiac
resynchronization therapy (CRT) between male and female
patients, but significant differences by gender were observed
for anticoagulant therapy, implantable cardioverter defibrilla-
tor/CRT-D therapy, and HF education, with higher rates
evident for men (p < 0.001 for all comparisons). Older
patients, particularly older women, were significantly less likely
to receive guideline-indicated HF therapies.
Conclusions: Patient age and gender were independently asso-
ciated with reduced rates of some, but not all, HF therapies
in outpatient cardiology practices. Older women are espe-
cially at risk.
Perspective: As the population ages, it is increasingly clear that
women have longer life spans than men. The findings of this
study that elderly women are receiving less optimal treatment
when compared to men is of concern. Bridging the gap
between evidence and practice should continue to be the goal
of the practicing clinician to improve HF care in the elderly,
particularly in women with HF (Heart Fail Clin 2007;3:xi-xii).  
Summary written by: Ragavendra R. Baliga, MBBS 
JACC Vol. 54, No. 2, 2009
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Associations of Dietary Long-Chain n-3 
Polyunsaturated Fatty Acids and Fish With
Biomarkers of Inflammation and Endothelial
Activation (From the Multi-Ethnic Study of
Atherosclerosis [MESA])
He K, Liu K, Daviglus ML, et al.
Am J Cardiol 2009;103:1238–1243.
Study Question: Is dietary intake of n-3 long-chain fatty acids
and fish consumption associated with inflammatory bio-
markers and markers of endothelial activation?
Methods: Data from the Multi-Ethnic Study of
Atherosclerosis (MESA) were used for this analysis. The
MESA cohort enrolled men and women (ages 45-84 years),
with no apparent cardiovascular disease at baseline, between
2000 to 2002. Data on demographic and lifestyle factors
were collected, including information on physical activity.
Fish and long-chain n-3 polyunsaturated fatty acid con-
sumption was collected with self-administered 127-item
food frequency questionnaires for diet over the prior year.
Results: A total of 5,677 men and women with no missing
dietary information were included. Compared to those in
the lowest quartile of polyunsaturated fatty acid consump-
tion, subjects in the highest quartile were more likely to be
female, physically active, and have a higher educational
level and household income, lower body mass index, and be
nonsmokers. Long chain n-3 polyunsaturated fatty acid
intake was inversely associated with plasma concentrations
of interleukin-6 (p = 0.01) and matrix metalloproteinase-3
(p = 0.03). Nonfried fish consumption was inversely related
to C-reactive protein (p = 0.045). Fried fish consumption
was inversely related to intercellular adhesion molecule-1 
(p < 0.01), but not with other biomarkers.
Conclusions: Dietary intake of long-chain n-3 polyunsaturated
fatty acids and fish was associated with biomarkers, which
suggest lower levels of inflammation and endothelial activa-
tion, and may explain the cardioprotective effects of fish
consumption observed in prior studies.
Perspective: These findings from a larger multiethnic obser-
vational cohort suggest that consumption of long-chain n-3
fatty acids can be recommended for cardiovascular preven-
tion. Additional information regarding the ratio of n-3 to
n-6 fatty acids in this cohort would add to these findings,
as some investigators hypothesize that consumption of n-6
fatty acids should be reduced in the typical western diet as a
cardiovascular prevention measure.  
Summary written by: Elizabeth A. Jackson, MD 
Prevention/Vascular
Association of HTRA1 Mutations and Familial
Ischemic Cerebral Small-Vessel Disease
Hara K, Shiga A, Fukutake T, et al.
N Engl J Med 2009;360:1729-1739.
Study Question: What gene is responsible for cerebral autosomal
recessive arteriopathy with subcortical infarcts and leukoen-
cephalopathy (CARASIL)?
Methods: Linkage analysis was performed in five families with
CARASIL. Sequencing of a candidate gene was performed.
Results: CARASIL is linked to a 2.4-Mb region on chromosome
10q, which contains the HTRA1 gene. HTRA1 is a serine pro-
tease that represses signaling by transforming growth factor beta
(TGF-β) family members. Two HTRA1 missense mutations and
one nonsense mutation resulted in protein products that had
comparatively low levels of protease activity and did not repress
signaling by the TGF-β family members. One nonsense muta-
tion resulted in the loss of HTRA1 protein by nonsense-
mediated decay of messenger RNA. Immunohistochemical analy-
sis of the cerebral small arteries in affected persons showed
increased expression of the extra domain-A region of fibronectin
and versican in the thickened tunica intima and of TGF-β1 in
the tunica media.
Conclusions: CARASIL is associated with mutations in the
HTRA1 gene. Findings indicated a link between repressed inhi-
bition of signaling by the TGF-β family and ischemic cerebral
small-vessel disease, alopecia, and spondylosis.
Perspective: The genetic cause for this autosomal recessive disor-
der is unclear. By studying cases from consanguineous families,
the authors were able to map and then sequence a candidate
gene, which appears to be causally related to this disease. Defects
in this gene are associated with a reduced capacity to repress sig-
naling by TGF-β family members. These findings have
important therapeutic implications, as agents targeting TGF-β
signaling may reduce complications of this disease.  
Summary written by: Daniel T. Eitzman, MD  
Aspirin in the Primary and Secondary Prevention of
Vascular Disease: Collaborative Meta-Analysis of
Individual Participant Data From Randomised Trials
Antithrombotic Trialists (ATT) Collaboration.
Lancet 2009;373:1849–1860.
Study Question: Low-dose aspirin is of definite and substantial
net benefit for many people who already have occlusive vascular
disease. What are the benefits and risks in primary prevention?
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Methods: The authors conducted a meta-analysis of six primary
prevention trials (95,000 individuals at low average risk,
660,000 person-years, 3,554 serious vascular events) and 16
secondary prevention trials (17,000 individuals at high average
risk, 43,000 person-years, 3,306 serious vascular events) that
compared long-term aspirin versus no aspirin. Primary end-
points were serious vascular events and major bleeds.
Conclusions are based on an intention-to-treat analysis of first
events during the scheduled treatment periods.
Results: Daily aspirin dose ranged from 75-500 mg, and one
study gave 325 mg aspirin every other day. In the primary pre-
vention trials, aspirin allocation yielded a 12% proportional
reduction in serious vascular events, due mainly to a reduction
of about a fifth in nonfatal MI, and no effect on coronary
heart disease death. The net effect on stroke was not signifi-
cant. Vascular mortality did not differ significantly. Aspirin
allocation increased major gastrointestinal and extracranial
bleeds (0.10% vs. 0.07% per year, p < 0.0001), and the main
risk factors for coronary disease were also risk factors for
bleeding. In the secondary prevention trials, aspirin allocation
yielded a greater absolute reduction in serious vascular events
(6.7% vs. 8.2% per year, p < 0.0001), with a nonsignificant
increase in hemorrhagic stroke, but reductions of about a fifth
in total stroke and in coronary events.
Conclusions: In primary prevention without previous disease,
aspirin is of uncertain net value, as the reduction in occlusive
events needs to be weighed against any increase in major
bleeds. Further trials are in progress.
Perspective: Results of the US Physicians Health Study led to
the present practice of low-dose aspirin in middle-aged and
older men whose risk of bleeding is low and in whom the
blood pressure is controlled. In contrast, results of the
Women’s Health Study led to guidelines suggesting aspirin for
women 65 years and older for stroke prevention, and consider-
ation of low-dose aspirin for women with an annual event rate
estimated at >1%. There is good reason to continue studies to
define optimal use of aspirin for primary prevention. Although
counterintuitive, two recent studies did not demonstrate a
value for low-dose aspirin for prevention of cardiovascular
events in diabetes. We need a better and safer antiplatelet drug
than aspirin for primary and secondary prevention. Of course
it is not likely that any new agent will be as cost-effective.  
Summary written by: Melvyn Rubenfire, MD 
Prevalence of Cardiovascular Disease Risk Factors
Among National Football League Players
Tucker AM, Vogel RA, Lincoln AE, et al.
JAMA 2009;301:2111–2119.
Study Question: What are the cardiovascular disease risk factors
in active National Football League (NFL) players, and how do
these compare with data from the CARDIA study?
Methods: Data from a cross-sectional study of 504 veteran foot-
ball players from a convenience sample of 12 NFL teams at
professional athletic training facilities between April and July
2007 were compared with men of the same age in the general
US population (CARDIA study, a population-based observa-
tional study of 1,959 participants ages 23-35 years recruited in
1985-1986). The prevalence of cardiovascular risk factors was
assessed in both groups.
Results: NFL players were less likely to smoke compared with the
CARDIA group. Despite being taller and heavier, NFL players
had significantly lower prevalence of impaired fasting glucose
(6.7% [n = 24]; 95% CI, 4.6%-8.7%; vs. 15.5% [n = 267]; 95%
CI, 13.8%-17.3%; p < 0.001). The groups did not differ in
prevalence of high total cholesterol and low-density lipoprotein
cholesterol (LDL-C), low high-density lipoprotein cholesterol
(HDL-C), or high triglycerides. Hypertension and prehyperten-
sion were significantly more common in NFL players than in
the CARDIA group (both p < 0.001). Large size measured by
body mass index (BMI) was associated with increased blood
pressure, LDL-C, triglycerides, and fasting glucose; and
decreased HDL-C.
Conclusions: Compared with a sample of healthy young-adult
men, a sample of substantially larger NFL players had a lower
prevalence of impaired fasting glucose, less reported smoking, a
similar prevalence of dyslipidemia, and a higher prevalence of
hypertension. Increased size was associated with increased car-
diovascular risk factors.
Perspective: Over the past 30 years, there has been a significant
increase in BMI of offensive and defensive NFL linemen; and in
2003, 26% of NFL players had a BMI ≥30 kg/m2. There is
debate about whether athletic fitness has a protective effect
against the health risks of obesity. This study reveals that some
cardiovascular risk factors are similar (dyslipidemia), some
(impaired fasting glucose, tobacco use) occur at a lower rate
among NFL players, and some (hypertension and prehyperten-
sion) occur at a higher rate. However, in this athletic population,
the clinical cardiovascular implications are not known. Although
this study also reveals that higher BMI is associated with more
cardiovascular risk factors, it is also unknown what cardiovascu-
lar risk factors and events these men would suffer if they did or
did not participate in professional football.  
Summary written by: David S. Bach, MD 
Microalbuminuria and Risk of Venous
Thromboembolism
Mahmoodi BK, Gansevoort RT, Veeger GM, et al., on behalf of the
Prevention of Renal and Vascular End-Stage Disease (PREVEND) 
Study Group.
JAMA 2009;301:1790–1797.
Study Question: Does the presence of microalbuminuria predispose
to venous thromboembolism (VTE)?
JACC Vol. 54, No. 2, 2009
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Methods: The authors presented data from PREVEND, a
prospective community-based cohort study of residents of
Groningen, the Netherlands, between the ages of 28-75,
who were not pregnant or receiving insulin, followed in two
cohorts: 1) those with urinary albumin concentration (UAC)
>10 mg/L, and 2) those with UAC <10 mg/L. Data collec-
tion included risk factors for cardiovascular and renal disease.
The main endpoint was symptomatic, verified VTE.
Controls were 2,592 participants randomly selected from
among those without microalbuminuria, and the exposure
cohort was 6,000 individuals with UAC >10 mg/L. 
Results: Among the 8,574 subjects were 129 episodes of VTE
over a mean follow-up of 8.6 years, for an annual incidence of
0.14% (95% confidence interval [CI], 0.11-0.19%). The
annual incidence ranged from 0.12% to 0.56% for participants
having urinary albumin excretion (UAE) <15 versus UAE
>300 mg/24-hour urine collection, respectively (p for trend 
< 0.001). Hazard ratio for VTE was 2.82 (95% CI, 1.21-6.61)
for those with UAE >300 mg per 24 hours versus those having
UAE <15 mg per 24 hours. Hazard ratio for VTE for those
with microalbuminuria versus normal albuminuria (UAE <30
mg per 24 hours) was 2.0 (95% CI, 1.34-2.98; p < 0.001). 
Conclusions: Microalbuminuria is independently associated with
an increased risk of VTE.
Perspective: Although the CIs were somewhat wide, there
appears to be a clear association between UAE and the risk for
DVT. Importantly, this risk was 'dose' related, going up in a
linear fashion with increasing concentrations of urinary albu-
min. It is increasingly well established that proteinuria is a risk
factor for cardiovascular and arterial thrombotic events. These
data extend this observation to VTE. Recent studies also
demonstrated that lipid-lowering therapy may be associated
with a decreased risk of VTE. It makes sense to include
microalbuminuria as a risk factor in the assessment of cardio-
vascular as well as VTE risk. What remains to be seen is if
therapy directed at the prevention or treatment of microalbu-
minuria—such as the use of angiotensin-converting enzyme
inhibitors—will reduce incidence of VTE.  
Summary written by: James B. Froehlich, MD 
Residual Thrombosis on Ultrasonography to Guide
the Duration of Anticoagulation in Patients With
Deep Venous Thrombosis
Prandoni P, Prins MH, Lensing AW, et al., for the AESOPUS
Investigators.
Ann Intern Med 2009;150:577–585.
Study Question: Can the results of ultrasound imaging be used
to determine the length of anticoagulation therapy in patients
with deep venous thrombosis (DVT)?
Methods: The authors reported a randomized, multicenter,
open-label trial of fixed duration anticoagulation (3 months
for warfarin for secondary thrombosis, or 6 months for
unprovoked thrombosis) versus flexible duration, ultra-
sonography-directed anticoagulation (stop warfarin when
veins recanalized on ultrasound). All study subjects had fol-
low-up at 3, 9, 15, 21, and 33 months after randomization.
Ultrasound imaging was performed at each visit for all sub-
jects. For those subjects assigned to flexible duration of
therapy, when venous recanalization was observed, anticoag-
ulation therapy was discontinued up to a maximum duration
of 9 (secondary DVT) or 21 (idiopathic DVT) months. 
Results: Among the 538 consecutive outpatients with a first
episode of acute proximal DVT, there were 46 (17.2%)
patients in the fixed duration group and 32 (11.9%) flexible
duration subjects that developed recurrent DVT. For the sub-
sets of subjects with unprovoked DVT, or secondary DVT,
the differences were not statistically significant. Major bleed-
ing rates did not differ significantly between the fixed
duration and flexible duration groups (two [0.7%] vs. four
[1.5%], respectively).
Conclusions: Tailoring duration of anticoagulation for DVT on
the basis of follow-up ultrasonography findings reduces the
rate of recurrent venous thromboembolism (VTE) in adults
suffering from proximal DVT.
Perspective: Current guidelines suggest at least considering
lifelong anticoagulation in patients with even a single episode
of VTE that is idiopathic. The current study suggests that
waiting for recanalization prior to discontinuing anticoagula-
tion therapy is associated with a decreased risk of recurrence
during the time period studied. One major problem with this
study, however, is that the length of follow-up after cessation
of anticoagulants was shorter in the ultrasound group. Prior
studies suggest that over a similar period of follow-up after
cessation of therapy, those patients with ongoing risk factors
tended to have similar rates of recurrence that were simply
delayed after a longer period of therapy. Another shortcoming
of this study is that it does not focus on the most important
clinical question. The study mixed secondary and idiopathic
DVT patients. The current literature would suggest that a
short duration of therapy (3 months) is adequate and associ-
ated with low recurrence rates in patients with secondary
DVT. Methods to determine duration of therapy for patients
with idiopathic or unprovoked DVT are needed, however,
given the reticence of most patients and clinicians to recom-
mend or undergo lifelong anticoagulation.  
Summary written by: James B. Froehlich, MD 
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